What is Biogen's revenue?

Biogen (BIIB) generated $9.9B in revenue over the trailing twelve months, up 1.2% year over year.

Is Biogen profitable?

Biogen reported $1.4B in net income over the trailing twelve months, a 14.3% net margin.

What are Biogen's profit margins?

Gross margin is 75.5% and operating margin is 22.9%, with a 14.3% net margin.

What is Biogen's earnings per share?

Biogen's diluted EPS over the trailing twelve months is $9.65.

Where does Biogen's income statement data come from?

Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Biogen BIIB Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$9.89B+2.2%	$9.68B-1.6%	$9.84B-3.3%	$10.17B-7.4%
Total cost of revenue	$2.4B+4.1%	$2.31B-8.8%	$2.53B+11.2%	$2.28B+8.0%
Gross profit	$7.49B+1.6%	$7.37B+0.9%	$7.3B-7.5%	$7.9B-11.0%
Gross margin	75.7%-0.4pp	76.1%+1.9pp	74.2%-3.4pp	77.6%-3.2pp
Research and development	$1.78B-10.2%	$1.98B-19.0%	$2.45B+9.6%	$2.23B-10.8%
Selling, general and administrative	$2.43B+1.2%	$2.4B-5.7%	$2.55B+6.1%	$2.4B-10.1%
Compensation and benefits	——	——	——	——
Depreciation and amortization	$779.9M+15.8%	$673.2M+36.1%	$494.8M-4.6%	$518.4M+6.3%
Restructuring charges	$48.6M+60.9%	$30.2M-86.2%	$218.8M+66.9%	$131.1M—
Impairment charges	$0—	——	——	——
Other operating expenses	——	——	——	——
Total costs & expenses	$8.33B+7.3%	$7.77B-9.0%	$8.54B+29.7%	$6.58B-24.6%
Interest expense	——	——	——	——
Interest income	——	——	——	——
Other income (expense), net	-$302.6M+11.9%	-$343.6M-8.9%	-$315.5M-104%	-$154.4M+85.9%
Net investment gains (losses)	——	——	——	——
Income before income taxes	$1.61B-15.4%	$1.91B+47.0%	$1.3B-63.9%	$3.59B+106%
Income tax expense	$270.7M-1.1%	$273.8M+102%	$135.3M-78.6%	$632.8M+1,108%
Net income	$1.34B-17.8%	$1.63B+40.6%	$1.16B-61.9%	$3.05B+95.8%
Net margin	13.6%-3.3pp	16.9%+5.1pp	11.8%-18.1pp	29.9%+15.8pp
Diluted earnings per share	$9.14-18.3%	$11.19+40.2%	$7.98-61.9%	$20.94+101%
Basic earnings per share	$9.16-18.4%	$11.22+39.7%	$8.03-61.8%	$21.01+101%
Weighted-average shares, diluted	587.5M+0.6%	583.8M+0.5%	581.1M-0.6%	584.6M-2.7%
Weighted-average shares, basic	585.7M+0.6%	582.1M+0.6%	578.6M-0.7%	582.7M-2.7%
Share-based compensation expense related to employee stock plans	——	——	——	——
Adjustments To Product Revenue Reserves Relating To Sales In Prior Years	——	——	——	——
Share-Based Payment Arrangement, Expense, after Tax	——	——	——	——
Amortization and impairment of acquired intangible assets	$515M+15.3%	$446.7M+85.7%	$240.6M-34.2%	$365.9M—
Amortization of acquired inventory step-up	——	——	——	——
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1	——	——	——	——
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect	——	——	——	——
Collaboration profit sharing/(loss reimbursement)	$290.2M+14.1%	$254.4M+16.3%	$218.8M+3,057%	-$7.4M-203%
Collaboration profit sharing/(loss reimbursement)	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——
Current Provisions Relating To Sales In Current Year	——	——	——	——
Deferred taxes	$361.6M+329%	-$158.1M—	——	-$168.6M—
Depreciation	——	——	——	——
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——
Effective tax rates	——	——	——	——
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount	——	——	——	——
Share-Based Payment Arrangement, Expense, Tax Benefit	——	——	——	——
Gain on sale of equity security	——	——	——	——
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings	-$33.6M—	——	$0-100%	$209.1M+312%
Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	——
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	——	——	——	——
Currency exchange and other	——	——	——	——
Income Tax Examination Estimate Of Possible Loss	——	——	——	——
Increase Decrease In Accrued Income Taxes Payable	-$958.1M-1,321%	$78.5M+126%	-$299M-110%	-$142.3M—
Accrued liabilities	$171.1M—	——	——	-$113.4M—
Changes in the fair value of equity securities	——	——	——	——
Increase (Decrease) in Inventories	$64.7M-76.4%	$273.8M—	——	$338.3M-26.8%
Increase (Decrease) in Other Operating Assets and Liabilities, Net	——	——	——	——
Interest In Subsidiary	——	——	——	——
Inventory Write Down	——	——	——	——
Settlement expense	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$301.9M+56.3%	-$691.4M—	——	-$1.75B+16.6%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$1.37B-71.6%	-$799.2M+80.5%	-$4.1B-339%	$1.72B+405%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$2.2B-23.3%	$2.88B+85.9%	$1.55B—	——
Number of reportable segments	——	——	——	——
Number of wholesalers	——	——	——	——
Other comprehensive income/(loss) before reclassifications	——	——	——	——
Lease impairment	$52.9M—	$0—	$0—	——
Unrealized gains (losses) on available-for-sale securities	——	——	——	——
Unrealized gains (losses) on hedge instruments	——	——	——	——
Foreign currency translation gains (losses)	——	——	——	——
Other comprehensive income (loss)	——	——	——	——
Other comprehensive income/(loss)	——	——	——	——
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	——	——	——	——
Other Noncash Income (Expense)	-$68.3M+57.2%	-$159.6M-7.7%	-$148.2M+28.8%	-$208.2M-3.0%
Other income, net (Note 6)	——	——	——	——
Other income, net	——	——	——	——
Payment for (Proceeds from) Other Investing Activity	-$42.9M-1,013%	$4.7M-58.4%	$11.3M+146%	-$24.6M—
Payment, Tax Withholding, Share-Based Payment Arrangement	——	——	——	——
Payments Returns Applied Against Product Revenue Reserves Relating To Current Year	——	——	——	——
Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year	——	——	——	——
Payments to Acquire Debt Securities, Available-for-Sale	——	$0-100%	$5.14B+49.1%	$3.45B-9.5%
Payments to acquire in process research and development	——	——	——	——
Payments to Acquire Intangible Assets	$31.6M-84.7%	$206.1M+499%	$34.4M+1,086%	$2.9M-84.6%
Payments to Acquire Property, Plant, and Equipment	$153.8M+0.1%	$153.7M-44.5%	$277M+15.3%	$240.3M-6.9%
Financing — other	——	——	-$6M-7.1%	-$5.6M+75.5%
Proceeds from maturities of marketable securities	——	——	——	——
(Purchases) refunds of spectrum licenses and other intangible assets, including deposits	——	——	——	——
Proceeds From Sale Of Other Investments	——	——	——	——
Gross realized gains (losses)	——	——	——	——
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	——	——	——	——
Reduction of research and development expense	——	——	——	——
Acquired in-process research and development, upfront and milestone expense	$471.8M+667%	$61.5M+270%	$16.6M—	——
Research and development expense	$1.78B-10.2%	$1.98B-19.0%	$2.45B+9.6%	$2.23B-10.8%
Acquired in-process research and development, upfront and milestone expense	——	——	——	——
Stock-based compensation	$290.8M-0.1%	$291.2M+10.2%	$264.2M+4.0%	$254.1M+6.5%
Share-based compensation expense included in total cost and expense	——	——	——	——
Issuance of vested restricted stock units	——	——	——	——
Issuance of common stock and reissuance of treasury stock under equity incentive plans, net of forfeitures, value	——	——	——	——
Stockholders' Equity, Other	——	——	——	——
Change in fair value of interest rate swap	——	——	——	——
Unrealized gains	——	——	——	——
Unrealized Loss on Derivatives	——	——	——	——
Add: dilutive effect of potential common shares (in shares)	——	——	——	——
EBITDA	$2.59B-6.4%	$2.77B+40.8%	$1.97B-56.3%	$4.5B+35.2%
EBITDA margin	26.2%-2.4pp	28.6%+8.6pp	20%-24.2pp	44.2%+13.9pp
EBIT	$1.81B-13.5%	$2.1B+42.4%	$1.47B-63.0%	$3.98B+40.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Biogen.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biogen's revenue?: Biogen (BIIB) generated $9.9B in revenue over the trailing twelve months, up 1.2% year over year.
Is Biogen profitable?: Biogen reported $1.4B in net income over the trailing twelve months, a 14.3% net margin.
What are Biogen's profit margins?: Gross margin is 75.5% and operating margin is 22.9%, with a 14.3% net margin.
What is Biogen's earnings per share?: Biogen's diluted EPS over the trailing twelve months is $9.65.
Where does Biogen's income statement data come from?: Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.